Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Carcinoma, Renal Cell 5Neoplasms 4Carcinoma, Hepatocellular 4Lung Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Ovarian Neoplasms 2Neoplasm, Residual 2NSCLC 2Kidney Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms, Second Primary 1Neoplasms by Site 1Lung Diseases 1Liver Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Imatinib Mesylate 14Dasatinib 5nilotinib 4bosutinib 4Cyclophosphamide 4fludarabine 3Vincristine 3Methotrexate 3Dexamethasone 3Cytarabine 3peginterferon alfa-2a 2fludarabine phosphate 2asciminib 2Prednisone 2Daunorubicin 2Azacitidine 2Acetaminophen 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1ponatinib 1olverembatinib 1flumatinib 1blinatumomab 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Tyrosine Kinase Inhibitors × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡